Page 311 - ஒன்றுபட்டது மாநிலங்களில் பத்திரங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
V999, an alleged «gold» coin, Rainer von Holst alias Jan Faber and Jakob B « Русский Еврей
rusjev.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rusjev.net Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
PLANO, Texas, April 6, 2021 /PRNewswire/ Viellis Group, Inc. has now achieved a level of transparency with its full registration with the United States Securities and Exchange Commission (S.E.C.)
The company s EDGAR file, including its Form Reg. D, may be viewed at its EDGAR file, here: Viellis EDGAR File
A copy of the offering memorandum may be downloaded at the project website at www.viellis-project.com.
Company President, Syed Al-Refaie, said: With the S.E.C. registration, the company is now able to focus its capital raising on its two core missions of raising capital for the full large scale rollout of Nova System, and raising capital so as to have the required cash on hand for the cash match requirements of the health technology grants as contained in both of the Biden stimulus bills.
SEATech Ventures Announces Client AsiaFIN Holdings Corp Obtained S-1 Notice of Effectiveness
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
News provided by
Share this article
Incyte logo. (PRNewsfoto/Eli Lilly and Company)
INDIANAPOLIS, April 6, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD).
The FDA extended the action date to allow time to review additional data analyses submitted by Lilly in response to recent information requests from the FDA. The Prescription Drug User Fee Act (PDUFA) action date has been extended three months to early Q3 2021.
Wipro appoints Sarah Adam–Gedge as Managing Director for Australia and New Zealand
Sydney, Australia
– April 6, 2021: Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the appointment of Sarah Adam–Gedge as the Managing Director for Australia and New Zealand (ANZ).
Sarah has proven experience in leading digital transformation initiatives for large organizations globally with a successful track record of driving growth, profitability, business agility and managing successful relationships with customers and the influencer ecosystem. She has worked in project and service-based consultancies for more than 25 years across Australia and New Zealand, Asia-Pacific, Middle East and Africa and Latin America.
vimarsana © 2020. All Rights Reserved.